In the drive to identify new therapeutic technologies, the pharma industry is increasingly looking to form strategic collaborations with other members of the industry in order to mix creative ideas and technical insight. For a successful outcome, it is important that both parties have a clear understanding of what each party is to gain from the collaboration. Identifying ownership of the technology that is used and developed in the collaboration â and protecting that technology using the appropriate national and international intellectual property rights â is an important first step according to Contract Pharma. If the ownership of such technology is not clearly understood, it is easy for disputes between the parties to arise.
At this year's World Animal Health Congress, we are glad to welcome Brinks Hofer Gilson & Lione's to our list of sponsors. Ryan Marshall, Partner, Brinks Hofer Gilson & Lione will be speaking at the event on the subject of avoiding ownership disputes in intellectual property collaborations. Marshall will address ensuring all parties are appropriately protected in early-stage development and steering clear of common IP pitfalls in academics and pharmaceutical partnerships.
Who are they? Brinks has more than 140 attorneys, scientific advisors and patent agents who specialize in intellectual property, making it one of the largest intellectual property law firms in the U.S. Clients around the world use Brinks to help them identify, protect, manage and enforce their intellectual property. Brinks lawyers provide expertise in all aspects of patent, trademark, unfair competition, trade secret and copyright law.
To learn more about solving ownership disputs in intellectual property collaborations and to meet with industry professionals, join us at the World Animal Health Congress.
Stay tuned with updates by connecting with us:
Twitter: @Biopharmaevents #WAHC
LinkedIn: : http://linkd.in/OMTK6g
See what's been going on with the event by checking out the World Animal Health Congress Activity Log